Effects of sodium-glucose co-transporter 2 inhibitor on metabolic parameters in patients with type 2 diabetes

Trial Profile

Effects of sodium-glucose co-transporter 2 inhibitor on metabolic parameters in patients with type 2 diabetes

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Apr 2017

At a glance

  • Drugs Canagliflozin (Primary) ; Dapagliflozin (Primary) ; Empagliflozin (Primary) ; Luseogliflozin (Primary) ; Tofogliflozin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Apr 2017 Planned no of patients changed from 85 to 150.
    • 05 Apr 2017 Status changed from completed to recruiting.
    • 05 Apr 2017 Treatment with only luseogliflozin is now replaced with class of sodium-glucose co-transporter 2 inhibitor which includes treatment with dapagliflozin/tofogliflozin/empagliflozin/canagliflozin. Effect of this class on glycemic control, serum lipids and genital infection will also be studied along with hepatic function now. Also completed trial has been restarted now.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top